Anixa Biosciences (NASDAQ: ANIX) investors approve directors, pay and auditor

Rhea-AI Filing Summary

Anixa Biosciences, Inc. held its 2026 annual meeting of stockholders on March 10, 2026. A total of 33,379,505 shares of common stock were entitled to vote, and 20,805,324 shares were present in person or by proxy, establishing a quorum.

Stockholders re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors to serve until the 2027 annual meeting or until successors are elected and qualified. They also approved, on a non-binding, advisory basis, the Company’s executive compensation and ratified the appointment of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026.

The company filed as an exhibit a management presentation used at the annual meeting, which may also be used in future meetings with investors, analysts, or others.

false 0000715446 0000715446 2026-03-10 2026-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2026

ANIXA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37492		11-2622630
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3150 Almaden Expressway, Suite 250 San Jose, CA		95118
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (408) 708-9808

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ANIX		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 10, 2026, Anixa Biosciences, Inc. (the “Company”) completed its 2026 annual meeting of stockholders (the “Annual Meeting”). The number of shares of stock entitled to vote at the Annual Meeting was 33,379,505 shares of common stock (the “Voting Stock”). The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was 20,805,324 shares. At the Annual Meeting, the Company’s stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company’s executive compensation, and (iii) ratified the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2026. The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

Proposal No. 1 - Election of directors

Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. were each re-elected to serve until the 2027 annual meeting of stockholders or until their successors are elected and qualified or until their earlier resignation or removal. The voting results were as follows:

Nominee		Shares Voted For				Shares Withheld				Broker Non-Vote
Dr. Amit Kumar			8,917,813				218,238				11,669,273
Dr. Arnold Baskies			7,425,900				1,710,151				11,669,273
Emily Gottschalk			7,249,290				1,886,761				11,669,273
Lewis H. Titterton, Jr.			7,176,739				1,959,312				11,669,273

Proposal No. 2 - Approval, by non-binding advisory vote, of the Company’s executive compensation

The Company’s executive compensation, by non-binding advisory vote, was approved. The voting results were as follows:

Votes For			Votes Against				Abstentions				Broker Non-Votes
6,025,247				2,973,752				137,032				11,669,273

Proposal No. 3 - Ratification of the appointment of independent registered public accounting firm

The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending October 31, 2026 was ratified. The voting results were as follows:

Shares Voted For			Shares Voted Against				Shares Abstaining				Broker Non-Vote
20,426,524				191,432				187,368				-

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report is the form of presentation of the Company which was used by management at its Annual Meeting. This presentation may be used by the Company in the future at meetings with investors, analysts or others, in whole or in part and possibly with modifications from time to time.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.		Description
99.1		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 11, 2026

	ANIXA BIOSCIENCES, INC.
	By:	/s/ Michael J. Catelani
	Name:	Michael J. Catelani
	Title:	President, Chief Operating Officer and Chief Financial Officer

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FAQ

What did Anixa Biosciences (ANIX) stockholders vote on at the 2026 annual meeting?

Stockholders voted on three key items: re-election of four directors, a non-binding advisory vote on executive compensation, and ratification of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026.

Were all Anixa Biosciences (ANIX) director nominees re-elected at the 2026 annual meeting?

Yes. Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. were each re-elected. They will serve until the 2027 annual meeting of stockholders or until their successors are elected and qualified or until earlier resignation or removal.

How many Anixa Biosciences (ANIX) shares were represented at the 2026 annual meeting?

Of 33,379,505 shares of common stock entitled to vote, 20,805,324 shares were present or represented by valid proxy. This level of participation established a quorum, allowing the company to conduct official business and approve the meeting proposals.

Did Anixa Biosciences (ANIX) stockholders approve executive compensation in 2026?

Yes. Stockholders approved the company’s executive compensation in a non-binding, advisory vote. The proposal received 6,025,247 votes for, 2,973,752 against, 137,032 abstentions, and 11,669,273 broker non-votes, indicating majority support among votes cast on the matter.

Which auditor did Anixa Biosciences (ANIX) ratify for the fiscal year ending October 31, 2026?

Stockholders ratified Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending October 31, 2026. The ratification received 20,426,524 shares voted for, 191,432 against, and 187,368 abstaining, with no broker non-votes reported.

What is Exhibit 99.1 in Anixa Biosciences’ March 2026 Form 8-K?

Exhibit 99.1 is a company presentation used by management at the 2026 annual meeting. The filing notes this presentation may also be used in future meetings with investors, analysts, or others, either in whole or in part and possibly with modifications.

Filing Exhibits & Attachments

25 documents

Press Releases

• EX-99.1 EX-99.1 15.2 KB
• EX-99 GRAPHIC 136.7 KB
• EX-99 GRAPHIC 262.8 KB
• EX-99 GRAPHIC 57.3 KB
• EX-99 GRAPHIC 231.6 KB
• EX-99 GRAPHIC 117.5 KB
• EX-99 GRAPHIC 228.4 KB
• EX-99 GRAPHIC 221.8 KB
• EX-99 GRAPHIC 228.4 KB
• EX-99 GRAPHIC 276.8 KB
• EX-99 GRAPHIC 171.8 KB
• EX-99 GRAPHIC 110.3 KB
• EX-99 GRAPHIC 182.4 KB
• EX-99 GRAPHIC 256.1 KB
• EX-99 GRAPHIC 322.8 KB
• EX-99 GRAPHIC 408.4 KB
• EX-99 GRAPHIC 200.7 KB
• EX-99 GRAPHIC 116.8 KB
• EX-99 GRAPHIC 230.7 KB
• EX-99 GRAPHIC 320.2 KB
• EX-99 GRAPHIC 206.3 KB
• EX-99 GRAPHIC 203.9 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB